firstminute capital’s Post

We are beyond thrilled to announce our $55m Series B funding round, led by Balderton Capital, with support from Visionaries Club, Creandum, firstminute capital, and Seedcamp. This marks an important milestone in our mission to deliver radically faster, more reliable clinical trials, and help life science companies achieve their full potential. Thanks to the sponsors we work with, our investors, and our incredible team including advisors Bob Langer and Tim Garnett, we’re continuing to challenge the status quo in clinical trials. This new funding will help us invest further in our AI and eClinical platform, Citrus™ and expand our clinical operations footprint across North America and Europe. Read our full announcement: https://lnkd.in/eqqxwe99 #clinicaltrials #startup #cro #venturecapital #biotech #pharma

🚀 Huge congratulations to the team at Lindus Health on raising $55M in venture capital! 🎉 This is a remarkable achievement and a clear signal of the incredible innovation you’re driving in the clinical trial space. The CRO industry has been shaped for decades by a handful of dominant players who control nearly half the market and generate billions in revenue annually. Meanwhile, smaller CROs often operate with tight margins and slower growth, leaving little room for the adoption of transformative technologies. This dynamic has created significant challenges for companies trying to modernize clinical trials. It’s inspiring to see Lindus Health stepping up to break through these barriers. By rethinking what’s possible in clinical trials, they’re not only addressing long-standing inefficiencies but also setting a new standard for how innovation can drive meaningful change in this space. Kudos to the founders Meri Beckwith, Michael Young, Nik Haldimann and team for tackling this challenge head-on and pushing the boundaries of what can be achieved. Your success inspires all of us who believe in bringing innovation to healthcare, especially clinical trials. #Innovation #ClinicalTrials #HealthTech

Enveda Biosciences Secures $55M to Advance AI-Driven Drug Discovery - Major Funding Round: Enveda Biosciences, a biotech firm specializing in AI-driven drug discovery, raised $55M in a Series B2 round, bringing total funding to $230M. - Strategic Investors: New investors include Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, with continued support from existing backers. - Advancing Drug Development: Funds will enhance Enveda’s AI platform and support Phase I clinical trials for three lead programs, including a novel treatment for atopic dermatitis. Subscribe to our daily newsletter here for more AI news https://lnkd.in/d_cKz6EH #AI #Healthcare #Innovation #Technology #Future #Startups #Entrepreneurship #VentureCapital #ArtificialIntelligence #DigitalMarketing

💊 Weight-loss drug developer Verdiva Bio just raised a massive $410m series A - one of the largest series A rounds in Europe's history. In fact, this single round is larger than the entire funding total for metabolism and weight management companies in Europe in 2024. The startup emerged from stealth with the announcement, with investors that included Lilly Asia Ventures 礼来亚洲基金, General Atlantic, Forbion, OrbiMed, Logos Capital & LYFE Capital.

Contract research organization Aragen Life Sciences secures a $100 million investment from private equity firm Quadria Capital, resulting in Quadria acquiring a minority stake in the company. The funds will be used to expand Aragen's capabilities and infrastructure to address the increasing demand for outsourced services from innovators in the US and Europe. ARAGEN is a trusted R&D and manufacturing partner specializing in Contract Development & Manufacturing Organization (CDMO) services. They assist clients in expediting their drug development processes, from discovery to commercialization. With a recent USD 100 million investment from private equity firm Quadria Capital, ARAGEN aims to expand its capabilities and infrastructure to cater to the increasing demand for outsourced services from innovators in the United States and Europe. As a result, they can better support integrated discovery and manufacturing services, ultimately helping customers bring their products to market faster and more efficiently. Factacy.ai Congratulates and wishes them well. #innovation #management #digitalmarketing #technology #creativity #futurism #startups

Bluenote, a five-year-old Austin startup that automates the creation of regulatory documents for pharmaceutical companies, enhancing efficiency and accuracy in their workflows, raised $10 million led by Lux Capital, with Elad Gil, Anthropic & Menlo Ventures Anthology Fund, McKesson Ventures, Electric Capital, Moxxie Ventures, and Carbon Silicon Ventures. https://lnkd.in/gWP6BjCj

New Post: Italian life sciences firm XGEN Venture closes debut fund - XGEN Venture, a Milan-based life sciences venture capital firm, has closed its inaugural fund at approximately €180 million, having aimed for €200 million. Founded in 2021 by Paolo Fundarò, Federica Draghi, and Daniele Scarinci, the firm has attracted significant investments from family office Micheli Associati, the European Investment Fund, and CDP Venture Capital. The fund focuses on early-stage investments in biotechnology, medical devices, and diagnostics, with six startups funded so far, including iOnctura BV. XGEN plans to make nine more investments in the next two to three years, emphasizing innovation's role in healthcare challenges. Read the full article here https://lnkd.in/dChuEFGQ #Venturecapital #VC #investment #LP #Limited Partner

Atlas Venture has announced its fourteenth fund, closing at $450 million to fuel biotech innovation. The firm has launched 16 new biotechs and supported acquisitions such as Eli Lilly’s of Versanis Bio and GSK’s $1 billion deal for Aiolos Bio. James Waldron | Fierce Biotech https://lnkd.in/eN2cyYEc #lifesciences

💸 Today's Interesting pick is focussing on Oss-based biotech company Citryll bags €85M funding to fight inflammatory diseases ⚜️ We request you all to comment on any exciting Startup irrespective of the location, We will do homework. 🚀 The Netherlands-based Citryll, a biotech company, announced on Monday that it has closed an oversubscribed €85M in a Series B funding round. 💡 The funding was co-led by Johnson & Johnson (through its corporate venture capital organisation, @Johnson & Johnson Innovation – JJDC, Inc.), Forbion, and Novartis Venture Fund 🔬 Others, including Pureos Bioventures, alongside existing investors BGV (BioGeneration Ventures) , Seventure Partners, BOM, Curie Capital, and Citryll’s founders, also participated in the round.  🏥 The company will use the funds to advance the clinical development of CIT-013. This first-in-class monoclonal antibody targets Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory process that has yet to be addressed therapeutically. Eduardo Bravo  Maarten Kraan Tim Schenk #Biotech #Citryll #AutoimmuneDiseases #FundingNews #BiotechInnovation #ClinicalTrials #NETsTherapies #HealthcareAdvancements #LifeSciences #RaisingCapital #InflammationResearch #ChronicDiseases #TherapeuticInnovation #PharmaStartups #BiotechFunding #MedicalBreakthroughs #PrecisionMedicine #DrugDiscovery #NetherlandsStartups #HealthTech #AutoimmuneTherapies #TransformingHealthcare #HealthInnovation #InvestorConfidence #FutureOfMedicine #GlobalHealthcare #ResearchAndDevelopment #MedicalInnovation #SustainableHealthcare #BiotechBreakthroughs

🔬 Biotech IPO Market Heats Up: 3 Startups Seek $400M Three healthcare startups are gearing up to raise up to $400 million in US IPOs, marking September as the busiest month for healthcare IPOs in 2024. Companies like Upstream Bio, CAMP4 Therapeutics, and CeriBell are looking to capitalize on potential Fed rate cuts through their IPOs. Here are the IPO details: - Upstream Bio: Targeting up to $212.5M - CAMP4 Therapeutics: Seeking $80M - CeriBell: Aiming for up to $107.2M Market trends indicate strong debuts by BioAge Labs (BIOA.O) and Bicara Therapeutics (BCAX.O), encouraging more listings. Investors are favoring companies with established business models and paths to profitability, while private equity and VC firms are pushing for exits. In context, the biotech IPO market is rebounding after a two-year slump, with the US presidential election potentially impacting funding activity later in the year. https://lnkd.in/evxEPW5S #BiotechIPO #HealthcareInvesting #VC